# A Study to Investigate the Effects of PF00610335 on the QT/QTC Interval in Healthy Volunteers

> **NCT01107054** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 48 (actual)

## Conditions studied

- Pulmonary Disease
- Lung Disease
- Moxifloxacin

## Interventions

- **DRUG:** PF-00610355
- **DRUG:** PF-00610355
- **DRUG:** moxifloxacin
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT01107054
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-06
- **Primary completion:** 2010-09
- **Final completion:** 2010-12
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2011-01-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01107054

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01107054, "A Study to Investigate the Effects of PF00610335 on the QT/QTC Interval in Healthy Volunteers". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01107054. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*